Christopher S. Boerner's most recent trade in Colgate-Palmolive Co. was a trade of 2,020 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 11, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Colgate-Palmolive | Christopher S. Boerner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2026 | 2,020 | 2,020 | - | - | Stock Option (Right to Buy) | |
| Colgate-Palmolive | Christopher S. Boerner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2026 | 1,383 | 1,383 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2026 | 156,735 | 156,735 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2026 | 104,490 | 104,490 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 40,398 | 47,382 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 40,398 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2026 | 19,835 | 27,547 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 17,788 | 34,817 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 17,788 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.13 per share. | 10 Mar 2026 | 10,518 | 17,029 (0%) | 0% | 60.1 | 632,447 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2026 | 8,734 | 26,083 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 6,733 | 6,733 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 6,733 | 10,784 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 6,618 | 0 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 6,618 | 7,800 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.13 per share. | 10 Mar 2026 | 4,632 | 21,451 (0%) | 0% | 60.1 | 278,522 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.13 per share. | 10 Mar 2026 | 3,073 | 6,984 (0%) | 0% | 60.1 | 184,779 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.13 per share. | 10 Mar 2026 | 3,006 | 4,051 (0%) | 0% | 60.1 | 180,751 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2026 | 743 | 7,057 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2026 | 727 | 10,057 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2025 | 2,964 | 2,964 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2025 | 2,964 | 5,930 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.07 per share. | 01 Nov 2025 | 1,238 | 1,182 (0%) | 0% | 46.1 | 57,035 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 01 Nov 2025 | 544 | 2,420 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Jun 2025 | 62,719 | 0 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Jun 2025 | 62,719 | 125,439 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 03 Jun 2025 | 62,720 | 62,719 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 03 Jun 2025 | 62,720 | 62,720 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 145,607 | 145,607 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 97,071 | 97,071 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 39,700 | 152,898 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 39,700 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 14,641 | 138,257 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 12,818 | 125,439 (0%) | 0% | 63.1 | 808,944 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 6,985 | 111,611 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 6,985 | 0 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 6,733 | 13,466 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 6,733 | 117,203 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 6,616 | 114,418 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 6,616 | 6,618 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 3,327 | 107,802 (0%) | 0% | 63.1 | 209,967 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 2,858 | 113,198 (0%) | 0% | 63.1 | 180,368 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 2,794 | 110,470 (0%) | 0% | 63.1 | 176,329 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 1,154 | 113,264 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 1,147 | 116,056 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 482 | 111,129 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 55.05 per share. | 20 Feb 2025 | 2,000 | 104,626 (0%) | 0% | 55.0 | 110,096 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 2,964 | 104,169 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 2,964 | 8,894 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 54.32 per share. | 01 Nov 2024 | 1,488 | 102,626 (0%) | 0% | 54.3 | 80,828 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 01 Nov 2024 | 55 | 104,114 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2024 | 148,026 | 148,026 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2024 | 98,684 | 98,684 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 41,910 | 129,769 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 41,910 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 14,589 | 115,180 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.79 per share. | 10 Mar 2024 | 13,975 | 101,205 (0%) | 0% | 53.8 | 751,715 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 6,985 | 92,020 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 6,985 | 6,985 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 6,733 | 20,199 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 6,616 | 13,234 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 5,743 | 0 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 5,743 | 88,415 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.79 per share. | 10 Mar 2024 | 2,957 | 87,859 (0%) | 0% | 53.8 | 159,057 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.79 per share. | 10 Mar 2024 | 2,475 | 85,035 (0%) | 0% | 53.8 | 133,130 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 1,204 | 90,816 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 905 | 87,510 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Boerner Christopher S. | Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 49.78 per share. | 05 Dec 2023 | 2,000 | 82,672 (0%) | 0% | 49.8 | 99,560 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Boerner S. Christopher | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2023 | 2,638 | 0 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb | Christopher Boerner S. | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2023 | 2,638 | 82,022 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Boerner S. Christopher | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.10 per share. | 02 Dec 2023 | 1,350 | 80,672 (0%) | 0% | 50.1 | 67,635 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Christopher S. Boerner | Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 48.86 per share. | 28 Nov 2023 | 3,071 | 79,384 (0%) | 0% | 48.9 | 150,049 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Christopher S. Boerner | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2023 | 17,788 | 17,788 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Christopher S. Boerner | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2023 | 11,858 | 11,858 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 40,398 | 40,398 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 34,450 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 34,450 | 91,880 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 26,932 | 26,932 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.71 per share. | 10 Mar 2023 | 19,773 | 76,313 (0%) | 0% | 65.7 | 1,299,284 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 6,985 | 13,970 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 6,985 | 57,108 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 6,616 | 19,850 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 6,616 | 60,710 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 5,741 | 52,541 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 5,741 | 5,743 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 5,319 | 48,573 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 5,319 | 0 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2023 | 4,206 | 96,086 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.71 per share. | 10 Mar 2023 | 4,160 | 54,094 (0%) | 0% | 65.7 | 273,354 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.71 per share. | 10 Mar 2023 | 3,713 | 46,800 (0%) | 0% | 65.7 | 243,981 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.71 per share. | 10 Mar 2023 | 3,494 | 57,430 (0%) | 0% | 65.7 | 229,591 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.71 per share. | 10 Mar 2023 | 3,480 | 50,123 (0%) | 0% | 65.7 | 228,671 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2023 | 1,940 | 50,513 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2023 | 1,146 | 58,254 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2023 | 1,062 | 53,603 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2023 | 214 | 60,924 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2022 | 2,637 | 2,638 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2022 | 2,637 | 44,603 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.13 per share. | 02 Dec 2022 | 1,349 | 43,254 (0%) | 0% | 81.1 | 109,444 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 69.20 per share. | 14 Mar 2022 | 29,532 | 41,966 (0%) | 0% | 69.2 | 2,043,526 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Christopher S. Boerner | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 39,700 | 39,700 | - | - | Performance Shares |